An experimental Lyme disease vaccine from Pfizer PFE0.40%increase; green up pointing triangle and Valneva VLA 0.93%increase; green up pointing triangle didn’t conclusively succeed in a large study, ...

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. The Ignite ...

Add Yahoo as a preferred source to see more of our stories on Google. Chairman and CEO of Pfizer Albert Bourla attends the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January ...

Pfizer is playing catch-up in the GLP-1 weight-loss space. The drugmaker is getting closer and closer to key patent cliffs. Investors should also note that Pfizer's payout ratio is worryingly high.

Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant ...

Pfizer is getting out of the business of developing and marketing HIV medicines by exiting its minority stake in ViiV Healthcare, a company the pharmaceutical giant formed in partnership with GSK 17 ...

Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...